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Introduction
The human body develops from a single cell into its final
adult form, which contains roughly 100 million, million
cells. In addition, many hundreds of millions of cells die
and are replaced daily, particularly in epithelial tissues
such as skin and the lining of the gastrointestinal tract.
Traumatic or chronic injury also stimulates tissue repair,
which involves much cell division. All of these processes
are controlled, at least in part, by families of proteins
called growth factors. These are usually small, membrane
impermeable proteins with receptors that are conse-
quently found, for at least part of their lifecycle, on the
surface of responsive cells.
Receptors
The family of growth factors and receptors described in
this series of reviews are known as the type 1 or EGF
family. In simpler organisms such as worms or flies the
family is a modest one, consisting of one receptor (Let 23)
and one ligand (Lin 3) in Caenorhabditis elegans, and one
receptor (DER) and four (Spitz, Gurken, Vein and Argos)
or possibly five (including Keren, a very recently described
gene) ligand genes in Drosophila melanogaster. Presum-
ably as a consequence of the greater size and complexity
of humans, this family has grown to consist of four recep-
tor genes (EGFR/HER1, c-erbB2/HER2, c-erbB3/HER3
and c-erbB4/HER4).
Each receptor protein has the same basic structure, con-
sisting of an extracellular amino-terminal domain, a single
transmembrane spanning sequence and an intracellular
cytoplasmic domain. This polypeptide chain is folded into
domains with specific functions. The extracellular domain is
divided into four regions based on two repeated
sequences, termed L1 and L2, which are responsible for
ligand recognition, and into further domains, termed S1 and
S2, which are rich in cysteine residues and provide a frame-
work on which to orientate the L1 regions. The transmem-
brane spanning sequence is far from the ‘passive spacer’ it
was originally believed to be, providing inter-receptor con-
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tacts that are important in dimerization. The cytoplasmic
domain contains three types of regions: the enzyme tyrosine
kinase; sites of phosphorylation on tyrosine that allow inter-
actions with intracellular second messenger systems (see
next article by Monilola Olayioye ‘Intracellular signaling path-
ways of ErbB2 and family members’); and sites of phospho-
rylation on serine and threonine residues that affect
properties such as ligand affinity.
Ligands
The 10 characterized human ligand genes encode two
distinct families that share a central ligand motif of approx-
imately 50 amino acids, containing three disulphide bonds
that stabilize the folded protein. The structure of this
region has now been determined by X-ray crystallography
[1] and by nuclear magnetic resonance [2]. The first group
of ligands that share the property of binding directly to the
EGF receptor are only produced in one form, but can be
processed by proteolytic cleavage into several forms. The
neuregulin genes (protein products of which bind to the c-
erbB3 and c-erbB4 receptors) produce a range of pro-
teins through splicing of alternative exons, and these are
further processed by glycosylation and proteolysis.
Signalling
Ligand binding induces receptor dimerization and
oligomerization. It is not currently clear whether both are
required for activating the cytoplasmic tyrosine kinase
domain, but the end result is that the receptor becomes
phosphorylated at specific sites in its own structure on the
hydroxyl groups of tyrosine residues. A complex interplay
of ligands in microenvironments induces selections of
receptor homodimers and heterodimers in individual cells.
Some combinations, particularly those including c-erbB2,
are more effective at promoting cell division due to their
greater affinity for ligands and their stability in the cell
membrane, which maintains their ability to signal for a
longer duration. Different receptors also have intrinsic abil-
ities to select different second messengers because of the
structure surrounding particular phosphorylation sites. The
selection of second messengers may be further compli-
cated by the use of different sites of phosphorylation in
heterodimers than in homodimers.
This rather complicated system [3] plays important roles in
development, wound healing and disease, notably in
cancer. Ligands may act at a distance, carried in the
bloodstream (endocrine); locally by diffusion (paracrine);
by cell-to-cell contact (juxtacrine); and possibly within cells
(intrakine). In natural settings, presumably the cell normally
receives stimuli from most if not all of these routes. Some
ligands, however, may be immobilized either on the
surface of cells by their own transmembrane region or by
other molecules such as heparan sulphate proteoglycans,
with which they interact by weaker electrostatic forces
and therefore can only act locally.
Cancer
During the more than 40 years of research carried out in
EGF signalling, our understanding has greatly increased
but there is clearly still a great deal to learn about its
normal functions. Although fascinating in itself, this
research has been further stimulated to an increasing
degree by the appreciation of the critical importance of
EGF signalling in cancer. Indeed, a significant amount of
research conducted by pharmaceutical companies is now
directed at exploiting this and closely related systems as
targets for drug development.
Cancer cells grow at a rate faster than that at which they
die; this is in contrast to cells in normal tissues, in which
the rate is balanced or slightly in favour of cell death. It
was originally hypothesized that cells cycled at their
fastest rate unless they were restrained in some way,
perhaps by nutritional or environment limitations, but also
by specific factors collectively termed chalones. Despite
much endeavour these remained elusive, sometimes with
the suspicious characteristic of becoming less active as
they became more pure. In the early 1960s, however, Rita
Levi-Montalcini purified nerve growth factor and Stanley
Cohen (a PhD student in her laboratory) purified EGF [4].
This protein was originally termed ‘tooth-lid factor’,
because the assay for its purification consisted of injecting
fractions into newborn mice and measuring the time
before their incisors erupted and their eyelids opened; this
is not an assay commonly used today!
This, and similar data on purified molecules, strongly sup-
ported the concept that cells required positive stimuli to
grow. Two observations were critical, fusing the field of
growth factor research with that of cancer: the discovery
that two retroviruses (simian sarcoma virus and avian ery-
throblastosis virus) contained a growth factor (platelet-
derived growth factor) [5,6] and a mutationally activated
growth factor receptor (EGF receptor), respectively, as
critical oncogenes [7]. Introduction and expression of
these proteins by the virus into susceptible animals or
animal cells in culture led to cell transformation. Loss of
expression or suppression of their activity made the cells
less oncogenic, thereby providing the paradigm that these
types of molecules may be responsible for the imbalance
in growth that is observed in cancer.
In parallel, work was beginning on the analysis of growth
factors and their receptors in human tumour specimens.
Hendler and Ozanne [8] first showed, by immunocyto-
chemical staining, that the EGF receptor was present at
abnormal levels in human lung cancers. The development
of antibodies that could detect expression of these recep-
tors and their ligands in paraffin-embedded, formalin-fixed
human tissues enabled larger series of cases to be exam-
ined [9]. Although being, in my view, far from complete in
terms of accuracy, scale and coverage of molecular types,Breast Cancer Research    Vol 3 No 6 Gullick
and certainly in terms of understanding of the information
contained, some generalizations have been developed
from this research.
Three mutually nonexclusive mechanisms lead to over-
activity of growth factor receptors (Fig. 1). Receptors may
be present in a normal form at a normal level, but be over-
active because of unusually high amounts of ligands pro-
duced by a variety of mechanisms. First, through an indirect
mechanism, mutations in genes such as Ras lead to
increased expression of EGF-like ligands, but it appears
that this may only augment cell transformation by Ras itself
[10]. Other receptors, in particular G-protein-coupled
receptors including gonadotrophin-releasing hormone
receptor, caused increased activity of the ADAM family of
metalloproteinases, which release active ligands from the
cell surface by proteolysis [11]. Gene amplification has not
reliably been reported as a mechanism for increased ligand
expression (which is an interesting observation because
amplification often causes receptor over-expression).
The second mechanism that causes over-activity of
growth factor receptor signalling is over-expression of a
normal growth factor receptor, either due to increased
transcription or gene amplification, or both. It is not clear
whether this requires the presence of some ligand or is
sufficient to increase the amount of active receptor
because of the equilibrium between monomer and dimers.
This may be somewhat academic, however, because it is
hard to conceive of a cell in an environment in which no
ligands exist, but it could have relevance to the choice of
and efficacy of different approaches to treatment.
Finally, growth factor receptors can be activated by point
mutations (such as the Ret gene in multiple endocrine neo-
plasia-2A, an inherited predisposition to cancer) [12] and
sporadically in the c-kit receptor (in gastrointestinal stromal
tumours), but thus far there is no reliable evidence for this
occurring in the type 1 receptor family. Deletion of various
parts of the EGF receptor gene is quite commonly found in
brain tumours, however [13]. The most frequent of these,
called the type III mutant EGF receptor, involves the dele-
tion of residues 6–273 in the extracellular domain. This
prevents ligand binding, but activates the receptor to
approximately 10% of the level achieved by saturating
ligand concentrations [14]. In this case the mutated gene
is also amplified, suggesting that this level of activation
does not achieve full transformation. Various reports have
suggested that the type III receptor is expressed at very
high prevalence in other tumour types, such as breast
cancer. However, the EGFR gene is very rarely amplified in
this type of disease and is even less frequently rearranged,
so the underlying mechanism producing it must differ, pos-
sibly involving tumour specific alternative splicing. In our
laboratory, however, we have not found evidence for the
mutant receptor by polymerase chain reaction analysis in
breast cancer cell lines, or by staining with a mutant recep-
tor protein specific antibody in primary, fixed breast cancer.
This issue is important to resolve, because it may be a very
promising target for treatment [14].
Treatment
Different points in the ligand/receptor lifecycles represent
targets for therapy (Fig. 1). Protease inhibitors can very
effectively prevent the release of cell surface growth
Figure 1
The epidermal growth factor family of ligands and receptors transform
cells by different mechanisms. (A) A cell may express a normal level of
receptors, but these are over-active because of the presence of excess
levels of one or more ligands. The mechanisms by which excessive
amounts of ligands are produced are not well established, but are not
due to gene amplification. Some evidence suggests that other
systems, such as G-protein-coupled receptors (GPCRs), may
influence ligand processing by metalloproteases. (B) A cell may over-
express a receptor as a result of either gene amplification or increases
in transcription, or both. (C) Some cancers, notably brain tumours,
express mutant receptors that are partly constitutively active. The
expression, processing and bioavailability of ligands can be targeted to
suppress their actions. Receptors can be targeted by antibodies,
which may inhibit ligand binding or have other activities, or by
antibodies fused with toxic molecules or with small molecule tyrosine
kinase inhibitors.factors, but their effects may be rather promiscuous, sug-
gesting that chronic use could have side effects. Inhibitors
of G-proteins or G-protein-coupled receptors could sup-
press growth factor production in diseases such as
prostate cancer, but clearly they may also have a more
direct effect.
It is possible to treat patients with antibodies to growth
factors or to induce immune responses to them, but it is likely
that several growth factors would have to be neutralized for
this to have significant effect. Other compounds, such as
suramin, mimic to some degree the proteoglycans that natu-
rally sequester growth factors. Clearly, there are opportuni-
ties to develop more specific, less toxic growth factor
neutralizing molecules. None of these strategies would a
priori be likely to affect the growth of cancers expressing
mutated receptors that have ligand independent activity.
The second strategy is to prevent receptor signalling more
directly. Antibodies have been made that inhibit ligand
binding and have been shown to generate responses in
patients [15]. Other antibodies such as Herceptin bind to
the extracellular domain of receptors in the same way but,
because their target c-erbB2 has no known directing
ligand, they presumably act by other mechanisms [16] In
the former case, the ligand blocking antibodies may be
effective in cells with normal or over-expressed receptors
as long as abundant ligand is present. Over-expressed
receptors could be a target for ligand or antibody linked
toxins, but paradoxically these are apparently so toxic that
normal tissues were also affected, resulting in unaccept-
able toxicity [17]. Mutant receptors can be targeted with
specific antibodies with or without cytotoxic functions
because they should be highly specific in their actions [14].
Finally, because excess receptor signalling is the outcome
in all of the examples discussed, inhibition of tyrosine kinase
activity using orally available small synthetic molecules may
be the most widely applicable strategy. These types of mol-
ecules may be required to be targeted very specifically,
because it is now clear that activation of molecules such as
c-erbB4 has antiproliferative effects [18] but it is not clear
how important this system is in cancer cells.
Although these approaches look very promising, there are
clearly some confounding issues, the most important
being side effects and the development of drug resis-
tance. Side effects may be on-target (i.e. by affecting the
receptor itself), off-target (i.e. via related proteins such as
other kinases), or nonspecific. They may be mediated via
the drug itself or by its metabolites. They may be acute or
chronic, reversible or irreversible. A common profile of
acute effects appears to be shared by two EGF receptor
antibodies and by tyrosine kinase inhibitors: acute acni-
form rash and diarrhoea, which resolve after withdrawal of
the drug.
The development of drug resistance is almost inevitable.
How long it will take to develop and what alternative path-
ways will become dominant are at present unpredictable.
If these pathways can be identified then it may be possible
to develop further drugs directed at them and patients
may be transferred to these if their cancer progresses.
Conclusion
The EGF family is involved through a variety of mecha-
nisms in the majority of epithelial cancers. Diagnosis of
these mechanisms in different tumour types and in individ-
ual patients will provide the rationale for clinical trials and
suggest the appropriate choice of drug. Undesirable side
effects and drug resistance may be minimized by the use
of different drugs used in combination or sequentially. The
encouraging prospect is that patients with breast and
other types of cancer, and the clinicians who treat them,
will have more effective, less toxic drugs available in the
relatively near future.
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